Nanoparticulate delivery can improve peroral bioavailability of cyclosporine and match neoral C-max sparing the kidney from damage

D. D. Ankola, R. M. Wadsworth, M. N. V. Ravi Kumar

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Cyclosporine (CsA) as an immunosuppressant has demonstrated immense potential in the field of organ transplantation and autoimmune disorders, despite the nephrotoxicity. The present investigation is an attempt to develop biodegradable nanoparticles entrapping CsA that can match C-max of Neoral (R), the most potent formulation available to date. The C-max and AUC(0-72) of CsA administered as nanoparticles demonstrated an increase with increase in the dose administered, however the relative bioavailability decreased. The C-max and AUC(0-72) increased from 682 to 1073 ng/ml and 34854 to 55322 ng . h/ml, respectively whereas, the relative bioavailability decreased from 120 to 64%. On the other hand, the increase in initial CsA loading (10-30% w/w of polymer) recorded a proportional increase in C-max and AUC(0-72), from 494 to 1101 ng/ml and 17774 to 51763 ng . h/ml, respectively. The relative bioavailability also increased from 31 to 89%. The CsA nanoparticles at 30% CsA loading w/w of polymer and at 30 mg/Kg single dose demonstrated comparable Cmax of Neoral (R) at 15 mg/Kg, which upon chronic administration over a period of 30 days daily dosing showed low nephrotoxicity to that exhibited by Neoral (R). The reduced toxicity of nanoparticulate CsA indicated by lower blood urea nitrogen, plasma creatinine and glomerular damage, was due to delay in T-max as result of slow release of the CsA from the nanoparticles. The investigation unlocks the potential of polymeric nanoparticles in oral delivery of CsA.

LanguageEnglish
Pages300-307
Number of pages8
JournalJournal of Biomedical Nanotechnology
Volume7
Issue number2
DOIs
Publication statusPublished - Apr 2011

Fingerprint

Nanoparticles
Cyclosporine
Biological Availability
Kidney
Area Under Curve
Polymers
Transplantation (surgical)
Nitrogen plasma
Blood Urea Nitrogen
Organ Transplantation
Immunosuppressive Agents
Urea
Toxicity
Creatinine
Blood

Keywords

  • biodegradable
  • bioavailability
  • nanoparticles
  • nephrotoxicity
  • oral delivery
  • enhanced oral bioavailability
  • renal-transplantation
  • A pharmacokinetics
  • liposome
  • efficacy
  • impact

Cite this

@article{fbe07cff3ce04522aadd20c892c9b072,
title = "Nanoparticulate delivery can improve peroral bioavailability of cyclosporine and match neoral C-max sparing the kidney from damage",
abstract = "Cyclosporine (CsA) as an immunosuppressant has demonstrated immense potential in the field of organ transplantation and autoimmune disorders, despite the nephrotoxicity. The present investigation is an attempt to develop biodegradable nanoparticles entrapping CsA that can match C-max of Neoral (R), the most potent formulation available to date. The C-max and AUC(0-72) of CsA administered as nanoparticles demonstrated an increase with increase in the dose administered, however the relative bioavailability decreased. The C-max and AUC(0-72) increased from 682 to 1073 ng/ml and 34854 to 55322 ng . h/ml, respectively whereas, the relative bioavailability decreased from 120 to 64{\%}. On the other hand, the increase in initial CsA loading (10-30{\%} w/w of polymer) recorded a proportional increase in C-max and AUC(0-72), from 494 to 1101 ng/ml and 17774 to 51763 ng . h/ml, respectively. The relative bioavailability also increased from 31 to 89{\%}. The CsA nanoparticles at 30{\%} CsA loading w/w of polymer and at 30 mg/Kg single dose demonstrated comparable Cmax of Neoral (R) at 15 mg/Kg, which upon chronic administration over a period of 30 days daily dosing showed low nephrotoxicity to that exhibited by Neoral (R). The reduced toxicity of nanoparticulate CsA indicated by lower blood urea nitrogen, plasma creatinine and glomerular damage, was due to delay in T-max as result of slow release of the CsA from the nanoparticles. The investigation unlocks the potential of polymeric nanoparticles in oral delivery of CsA.",
keywords = "biodegradable, bioavailability, nanoparticles, nephrotoxicity, oral delivery, enhanced oral bioavailability, renal-transplantation, A pharmacokinetics, liposome, efficacy, impact",
author = "Ankola, {D. D.} and Wadsworth, {R. M.} and Kumar, {M. N. V. Ravi}",
year = "2011",
month = "4",
doi = "10.1166/jbn.2011.1278",
language = "English",
volume = "7",
pages = "300--307",
journal = "Journal of Biomedical Nanotechnology",
issn = "1550-7033",
number = "2",

}

Nanoparticulate delivery can improve peroral bioavailability of cyclosporine and match neoral C-max sparing the kidney from damage. / Ankola, D. D.; Wadsworth, R. M.; Kumar, M. N. V. Ravi.

In: Journal of Biomedical Nanotechnology, Vol. 7, No. 2, 04.2011, p. 300-307.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Nanoparticulate delivery can improve peroral bioavailability of cyclosporine and match neoral C-max sparing the kidney from damage

AU - Ankola, D. D.

AU - Wadsworth, R. M.

AU - Kumar, M. N. V. Ravi

PY - 2011/4

Y1 - 2011/4

N2 - Cyclosporine (CsA) as an immunosuppressant has demonstrated immense potential in the field of organ transplantation and autoimmune disorders, despite the nephrotoxicity. The present investigation is an attempt to develop biodegradable nanoparticles entrapping CsA that can match C-max of Neoral (R), the most potent formulation available to date. The C-max and AUC(0-72) of CsA administered as nanoparticles demonstrated an increase with increase in the dose administered, however the relative bioavailability decreased. The C-max and AUC(0-72) increased from 682 to 1073 ng/ml and 34854 to 55322 ng . h/ml, respectively whereas, the relative bioavailability decreased from 120 to 64%. On the other hand, the increase in initial CsA loading (10-30% w/w of polymer) recorded a proportional increase in C-max and AUC(0-72), from 494 to 1101 ng/ml and 17774 to 51763 ng . h/ml, respectively. The relative bioavailability also increased from 31 to 89%. The CsA nanoparticles at 30% CsA loading w/w of polymer and at 30 mg/Kg single dose demonstrated comparable Cmax of Neoral (R) at 15 mg/Kg, which upon chronic administration over a period of 30 days daily dosing showed low nephrotoxicity to that exhibited by Neoral (R). The reduced toxicity of nanoparticulate CsA indicated by lower blood urea nitrogen, plasma creatinine and glomerular damage, was due to delay in T-max as result of slow release of the CsA from the nanoparticles. The investigation unlocks the potential of polymeric nanoparticles in oral delivery of CsA.

AB - Cyclosporine (CsA) as an immunosuppressant has demonstrated immense potential in the field of organ transplantation and autoimmune disorders, despite the nephrotoxicity. The present investigation is an attempt to develop biodegradable nanoparticles entrapping CsA that can match C-max of Neoral (R), the most potent formulation available to date. The C-max and AUC(0-72) of CsA administered as nanoparticles demonstrated an increase with increase in the dose administered, however the relative bioavailability decreased. The C-max and AUC(0-72) increased from 682 to 1073 ng/ml and 34854 to 55322 ng . h/ml, respectively whereas, the relative bioavailability decreased from 120 to 64%. On the other hand, the increase in initial CsA loading (10-30% w/w of polymer) recorded a proportional increase in C-max and AUC(0-72), from 494 to 1101 ng/ml and 17774 to 51763 ng . h/ml, respectively. The relative bioavailability also increased from 31 to 89%. The CsA nanoparticles at 30% CsA loading w/w of polymer and at 30 mg/Kg single dose demonstrated comparable Cmax of Neoral (R) at 15 mg/Kg, which upon chronic administration over a period of 30 days daily dosing showed low nephrotoxicity to that exhibited by Neoral (R). The reduced toxicity of nanoparticulate CsA indicated by lower blood urea nitrogen, plasma creatinine and glomerular damage, was due to delay in T-max as result of slow release of the CsA from the nanoparticles. The investigation unlocks the potential of polymeric nanoparticles in oral delivery of CsA.

KW - biodegradable

KW - bioavailability

KW - nanoparticles

KW - nephrotoxicity

KW - oral delivery

KW - enhanced oral bioavailability

KW - renal-transplantation

KW - A pharmacokinetics

KW - liposome

KW - efficacy

KW - impact

UR - http://www.scopus.com/inward/record.url?scp=79960997021&partnerID=8YFLogxK

U2 - 10.1166/jbn.2011.1278

DO - 10.1166/jbn.2011.1278

M3 - Article

VL - 7

SP - 300

EP - 307

JO - Journal of Biomedical Nanotechnology

T2 - Journal of Biomedical Nanotechnology

JF - Journal of Biomedical Nanotechnology

SN - 1550-7033

IS - 2

ER -